Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13805073 | 0.89 | PTGS1 (0.47) | PTGS1GSTK1GLO1NOD1 | |
| SCHEMBL628352 | 0.89 | GLO1 (0.49) | PTGS1GSTK1GLO1NOD1 | |
| SCHEMBL2957092 | 0.87 | PTGS1 (0.52) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL2534816 | 0.85 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL2530952 | 0.85 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL3721473 | 0.85 | PTGS1 (0.52) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Bromide SCHEMBL4250677 | 0.85 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL28191391 | 0.84 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL28191352 | 0.84 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL1147641 | 0.83 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149540-A1 | Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury | UNIVERSITY OF ROCHESTER | 2009-06-11 | — | — | US | disclosed |
| EP-1965650-A2 | COMPOSITIONS AND METHODS FOR ATTENUATING MITOCHONDRIA-MEDIATED CELL INJURY | University of Rochester (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007076322-A2 | COMPOSITIONS AND METHODS FOR ATTENUATING MITOCHONDRIA-MEDIATED CELL INJURY | UNIVERSITY OF ROCHESTER (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060122267-A1 | Compositions and methods for attenuating mitochondria-mediated cell injury | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149540-A1 | Compositions and Methods for Attenuating Mitochondria-Mediated Cell Injury | SHMT2, TXN2, TXNRD2 | PTGS1 219/4885GSTK1 164/4885GLO1 273/4885 |
| US-20060122267-A1 | Compositions and methods for attenuating mitochondria-mediated cell injury | SHMT2, TXN2, TXNRD2 | PTGS1 222/4885GSTK1 165/4885GLO1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.